JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
JERSEY, Channel Islands, May 09, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the UBS Global Healthcare Conference on Tuesday, May 23, 2017 at 10:30 a.m. Eastern Time at the Grand Hyatt New York. Also participating in the conference will be the Company’s Chief Financial Officer, Chris Lindop.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
